News TFF Pharmaceuticals, Inc.

Equities

TFFP

US87241J2033

Real-time Estimate Cboe BZX Other stock markets 11:36:12 2024-05-07 am EDT			5-day change	1st Jan Change
2.325 ^USD	+7.64%		-16.03%	-67.34%

Apr. 30	TFF Pharmaceuticals Prices $4.8 Million Public Offering; Shares Down Pre-Bell	MT
Apr. 29	TFF Pharmaceuticals, Inc. Makes Available Phase 2 Data from Tacrolimus Inhalation Powder for Prevention of Lung Transplant Rejection Presented at Recent ISHLT Annual Meeting	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TFF Pharmaceuticals Prices $4.8 Million Public Offering; Shares Down Pre-Bell	Apr. 30	MT
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering	Apr. 29	AQ
TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting	Apr. 29	AQ
TFF Pharmaceuticals, Inc. Makes Available Phase 2 Data from Tacrolimus Inhalation Powder for Prevention of Lung Transplant Rejection Presented at Recent ISHLT Annual Meeting	Apr. 29	CI
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions	Apr. 16	AQ
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions	Apr. 15	AQ
TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions	Apr. 15	CI
TFF Pharmaceuticals Files Equities Shelf	Apr. 08	MT
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 28	AQ
Earnings Flash (TFFP) TFF PHARMACEUTICALS Reports Q4 Revenue $114.3M	Mar. 28	MT
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28	CI
TFF Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Roth MKM Cuts TFF Pharmaceuticals' Price Target to $44 From $56, Maintains Buy Rating	Mar. 28	MT
Transcript : TFF Pharmaceuticals, Inc. - Special Call	Mar. 27
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs	Mar. 27	AQ
TFF Pharmaceuticals, Inc. Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (Tff VORI) Clinical Programs	Mar. 27	CI
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting	Mar. 25	AQ
TFF Pharmaceuticals Sells Stock in Registered Direct Offering	Mar. 20	MT
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	Mar. 20	AQ
TFF Pharmaceuticals Announces Update on Clinical Programs	Mar. 20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News TFF Pharmaceuticals, Inc.

Equities

TFFP

US87241J2033

Summary

Filters